Citation

Ren X, Pan X, Zhang Z, Wang D, Lu X, Li Y, Wen D, Long H, Luo J, Feng Y, Zhuang X, Zhang F, Liu J, Leng F, Lang X, Bai Y, She M, Tu Z, Pan J, Ding K, Ding K.: Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem, Volume 56 (3), 2013

Authors

Bai Y, Ding K, Ding K., Feng Y, Lang X, Leng F, Li Y, Liu J, Long H, Lu X, Luo J, Pan J, Pan X, Ren X, She M, Tu Z, Wang D, Wen D, Zhang F, Zhang Z, Zhuang X

Journal

J Med Chem

Year

2013

DOI

10.1021/jm301581y

PubMed

23301703

Machine-readable

REST APIRDF